Zacks Investment Research upgraded shares of Fate Therapeutics (NASDAQ:FATE) from a hold rating to a buy rating in a report published on Tuesday. Zacks Investment Research currently has $7.50 price objective on the biopharmaceutical company’s stock.

According to Zacks, “Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California. “

Other analysts also recently issued reports about the stock. HC Wainwright reiterated a buy rating and issued a $7.00 price target on shares of Fate Therapeutics in a research report on Wednesday, December 13th. Raymond James Financial reissued a buy rating on shares of Fate Therapeutics in a research note on Tuesday, December 12th. BMO Capital Markets reissued a buy rating and set a $7.00 target price on shares of Fate Therapeutics in a research note on Thursday, November 2nd. ValuEngine raised Fate Therapeutics from a sell rating to a hold rating in a research note on Sunday, December 31st. Finally, Wedbush reissued an outperform rating and set a $7.00 target price on shares of Fate Therapeutics in a research note on Monday, December 18th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The company has an average rating of Buy and an average price target of $7.64.

Shares of Fate Therapeutics (NASDAQ:FATE) traded up $0.10 during trading hours on Tuesday, hitting $6.80. 409,300 shares of the company were exchanged, compared to its average volume of 577,475. The firm has a market cap of $354.33, a P/E ratio of -7.16 and a beta of 1.52. The company has a quick ratio of 7.21, a current ratio of 7.21 and a debt-to-equity ratio of 0.32. Fate Therapeutics has a 1-year low of $2.52 and a 1-year high of $7.25.

Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). The firm had revenue of $1.03 million during the quarter, compared to analyst estimates of $0.95 million. Fate Therapeutics had a negative net margin of 935.09% and a negative return on equity of 64.55%. The company’s revenue for the quarter was up .0% on a year-over-year basis. equities analysts anticipate that Fate Therapeutics will post -0.99 earnings per share for the current year.

In other news, General Counsel Cindy Tahl sold 8,091 shares of the firm’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $3.85, for a total transaction of $31,150.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Daniel D. Shoemaker sold 13,225 shares of the firm’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $3.87, for a total transaction of $51,180.75. The disclosure for this sale can be found here. 10.88% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of the company. Hochman Cole Investment Advisors Inc. bought a new position in shares of Fate Therapeutics during the 3rd quarter worth approximately $158,000. New York State Common Retirement Fund bought a new position in shares of Fate Therapeutics during the 2nd quarter worth approximately $131,000. Rhumbline Advisers bought a new position in shares of Fate Therapeutics during the 2nd quarter worth approximately $133,000. Russell Investments Group Ltd. bought a new position in shares of Fate Therapeutics during the 3rd quarter worth approximately $234,000. Finally, Schwab Charles Investment Management Inc. bought a new position in shares of Fate Therapeutics during the 2nd quarter worth approximately $214,000. 49.85% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Fate Therapeutics (FATE) Upgraded to Buy by Zacks Investment Research” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.thecerbatgem.com/2018/01/12/fate-therapeutics-fate-upgraded-to-buy-by-zacks-investment-research.html.

About Fate Therapeutics

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Get a free copy of the Zacks research report on Fate Therapeutics (FATE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Fate Therapeutics (NASDAQ:FATE)

Receive News & Stock Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related stocks with our FREE daily email newsletter.